arrow
N

Nuttapong Ngamphaiboon

Mahidol University
H指数:24
被引数:9,152

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Landscape of industry-sponsored oncology trials across the Thai Society of Clinical Oncology (TSCO): a 12-year multicenter analysis

泰国临床肿瘤学会(TSCO)赞助的肿瘤学试验全景:一项为期12年的多中心分析

2026-07-310
OA
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status

卡博替尼与安慰剂在既往接受过血管内皮生长因子受体靶向治疗、放射性碘难治性分化型甲状腺癌患者中的比较(COSMIC-311):根据BRAF状态分析结局

2026-03-040
OAAI
Postoperative Radiation With or Without Concurrent Chemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma With Multiple Intermediate Risks: A Propensity Score-Matched Study

术后放疗联合或不联合同期化疗治疗具有多种中危因素局部晚期头颈部鳞状细胞癌患者:一项倾向性评分匹配研究

2025-03-070
OA
Changing Landscape of Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma Treatment and Survival Trends in Thailand: A 13-Year Multicenter Retrospective Study of Patients
2025-01-010
OA
Pharmacogenomic landscape of the Thai population from genome sequencing of 949 individuals
2024-12-280
OAAI
Predictive MINT pathological risk score for adjuvant chemotherapy in resected cholangiocarcinoma: A propensity score matched multicenter study in Thailand

预测性MINT病理风险评分在切除后胆管癌辅助化疗中的应用:一项在泰国进行的倾向性评分匹配的多中心研究

2024-12-010
PRE
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Pembrolizumab单药治疗与化疗在铂类预处理,复发或转移性鼻咽癌中的比较 (KEYNOTE-122): 一项开放标签,随机,III期试验

2023-03-0138
OAAI
Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study
2022-12-0110
OAAI